ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Pfizer at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Pfizer takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8031. Its program centres on advanced non-small cell lung cancer, including seven-year trial results in first-line ALK-positive disease that point towards managing it as a chronic condition, and new antibody therapies. It also covers individualised treatment decisions in metastatic breast cancer.

OrganizationESMO 2026 Attendance
Large pharmaExhibitor
Global pharmaceutical company whose oncology portfolio spans breast, lung, prostate, bladder and blood cancers, including antibody-drug conjugates from its Seagen acquisition.
Booth
Exhibiting at Booth 8031
Satellite
Sat Oct 24
13:00–14:30
Satellite
Sat Oct 24
18:30–20:00
Pfizer - Breaking the Treatment Plateau in Advanced NSCLC: Antibody Therapy Redefined
Sponsored session · with University of Chicago, Hospital Clínic de Barcelona, University Hospital Cologne
Lung & thoracic cancers
Satellite
Sun Oct 25
18:30–20:00
Pfizer Oncology - Metastatic Breast Cancer: Individualised Decision- Making in Focus
Sponsored session · with Hospital Arnau de Vilanova
Breast cancer

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Pfizer

Tell us what you sell and we’ll find the people at Pfizer most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction